Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted early, propelling the company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results